Valuation & Market

A new clinical trial in Malaysia could democratize advanced cancer care, testing an affordable, donor-derived immunotherapy challenging costly personalized treatments.

For 14 straight years, Hamilton Lane has been a 'Best Place to Work.' We analyze why this cultural consistency is its most potent strategic asset.

Chile's state oil firm is using strong profits to buy back $150M in debt. Is this just smart accounting, or a move to fund its green hydrogen ambitions?

A routine filing from a quant fund reveals subtle shifts in the high-stakes merger of American Axle and Dowlais. What does it mean for the bottom line?

A shareholder lawsuit challenges Comerica's $10.9B sale to Fifth Third, citing a rushed process, CEO self-interest, and an undervalued price.

Pershing Square's latest share repurchase is more than routine; it's a strategic move to close a stubborn valuation gap and signal deep confidence.